Safety and Efficacy of OBX-115 in Advanced Solid Tumors

This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

Trial Details

NCT ID
NCT06060613
Phase
PHASE1 / PHASE2
Sponsor
Obsidian Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • OBX-115
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Los Angeles, California, United States|34.05223,-118.24368
  • Stanford, California, United States|37.42411,-122.16608
  • Orlando, Florida, United States|28.53834,-81.37924
  • Louisville, Kentucky, United States|38.25424,-85.75941

Key Eligibility Criteria

  • Participant must be 18 years of age or older at the time of signing the informed consent.
  • Participant has a histologically confirmed diagnosis of advanced/metastatic melanoma or relapsed refractory metastatic non-small cell lung cancer (…
  • Cohort and indication specific criteria as follows:
  • Phase 1 and Phase 2 Cohort 1 (enrollment complete):

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →